51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer
Published: Sep 1, 2019
Abstract
Objectives
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of irinotecan. This study aimed to evaluate the efficacy of SG in primary EOC cell lines and xenografts.Methods
Trop-2...Paper Details
Title
51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer
Published Date
Sep 1, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History